Monocyte chemoattractant protein-1: Plasma concentrations and A(-2518)G promoter polymorphism of its gene in systemic lupus erythematosus

Journal of Rheumatology

Volumn 34, Issue 4, 2007, Pages 740-746

  Brown, Karen S ^a,c   Nackos, Eleni ^b   Morthala, Suneetha ^b   Jensen, Liselotte E ^a   Whitehead, Alexander S ^a   Von Feldt, Joan M ^b,d  

^a Center for Pharmacogenetics   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c DAIICHI SANKYO INC   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

CCL 2; Homocysteine; Inflammatory disease; Monocyte chemoattractant protein 1; Nephritis; Systemic lupus erythematosus

Indexed keywords

GENE PRODUCT; HOMOCYSTEINE; MONOCYTE CHEMOTACTIC PROTEIN 1; PREDNISONE; PROTEIN CCL 2 A; UNCLASSIFIED DRUG;

ADULT; AFRICAN AMERICAN; ALLELE; ARTERY CALCIFICATION; ARTICLE; CAUCASIAN; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; FEMALE; GENETIC ASSOCIATION; GENETIC DIFFERENCE; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOTE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; NEPHRITIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; RISK ASSESSMENT; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; AFRICAN AMERICANS; CALCINOSIS; CASE-CONTROL STUDIES; CHEMOKINE CCL2; CORONARY VESSELS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HOMOCYSTEINE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; NEPHRITIS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS (GENETICS);

EID: 34247326091     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Noris M, Bernasconi S, Casiraghi F, et al. Monocyte chemoattractant protein-1 is excreted in excessive amounts in the urine of patients with lupus nephritis. Lab Invest 1995;73:804-9.
2. Wada T, Yokoyama H, Su SB, et al. Monitoring urinary levels of monocyte chemotactic and activating factor reflects disease activity of lupus nephritis. Kidney Int 1996;49:761-7.
3. Rovin BH, Song H, Birmingham DJ, Hebert LA, Yu CY, Nagaraja HN. Urine chemokines as biomarkers of human systemic lupus erythematosus activity. J Am Soc Nephrol 2005;16:463-73.
4. Hasegawa H, Kohno M, Sasaki M, et al. Antagonist of monocyte chemoattractant protein 1 ameliorates the initiation and progression of lupus nephritis and renal vasculitis in MRL/lpr mice. Arthritis Rheum 2003;48:2555-66.
5. Zoja C, Corna D, Benedetti G, et al. Bindarit retards renal disease and prolongs survival in murine lupus autoimmune disease. Kidney Int 1998;53:726-34.
6. Alonso-Villaverde D, Coll B, Parra S, et al. Atherosclerosis in patients infected with HIV is influenced by a mutant monocyte chemoattractant protein-1 allele. Circulation 2004;40:2204-9.
7. Deo R, Amit K, McGuire DK, et al. Association among plasma levels of monocyte chemoattractant protein-1, traditional cardiovascular risk ractors, and subclinical atherosclerosis. J Am Coll Cardiol 2004;44:1812-8.
8. Von Feldt JM, Scalzi LV, Cucchiara AJ, et al. Homocysteine levels and disease duration independently correlate with coronary artery calcification in systemic lupus erythematosus patients. Arthritis Rheum 2006;54:2220-7.
9. Desai A, Lankford HA, Warren JS. Homocysteine augments cytokine-induced chemokine expression in human vascular smooth muscle cells: implications for atherogenesis. Inflammation 2001;25:179-86.
10. Zhang R, Jing M, Xia M, Zhu H, Ling W. Mild hyperhomocysteinemia induced by feeding rats diets rich in methionine or deficient in folate promotes early atherosclerotic inflammatory processes. J Nutr 2004;134:825-30.
11. Poddar R, Sivasubramanian N, DiBello PM, Robinson K, Jacobsen DW. Homocysteine induces expression and secretion of monocyte chemoattractant protein-1 and interleukin-8 in human aortic endothelial cells: implications for vascular disease. Circulation 2001;103:2717-23.
12. Sung FL, Slow YL, Wang G, Lynn EG, O K. Homocysteine stimulates the expression of monocyte chemoattractant protein-1 in endothelial cells leading to enhanced monocyte chemotaxis. Mol Cell Biochem 2001;216:121-8.
13. Zeng XK, Remick DG, Wang X. Homocysteine induces production of monocyte chemoattractant protein-1 and interleukin-8 in cultured human whole blood. Acta Pharmacol Sin 2004;25:1419-25.
14. Rovin BH, Lu L, Saxena R. A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression. Biochem Biophys Res Commun 1999;259:344-8.
15. Fenoglio C, Galimberti D, Lovati C, et al. MCP-1 in Alzheimer's disease patients: A-2518G polymorphism and serum levels. Neurobiol Aging 2004;25:1169-73.
16. Tucci M, Barnes EV, Sobel ES, et al. Strong association of a functional polymorphism in the monocyte chemoattractant protein 1 promoter gene with lupus nephritis. Arthritis Rheum 2004;50:1842-9.
17. Aguilar F, Gonzalez-Escribano MF, Sanchez-Roman J, Nunez-Roldan A. MCP-1 promoter polymorphism in Spanish patients with systemic lupus erythematosus. Tissue Antigens 2001;58:335-8.
18. Hwang S-Y, Cho M-L, Park B, et al. Allelic frequency of the MCP-1 promoter -2518 polymorphism in the Korean population and in Korean patients with rheumatoid arthritis, systemic lupus erythematosus and adult-onset Still's disease. Eur J Immunogenet 2002;29:413-6.
19. Kim HL, Lee DS, Yang SH, et al. The polymorphism of monocyte chemoattractant protein-1 is associated with the renal disease of SLE. Am J Kidney Dis 2002;40:1146-52.
20. Liao CH, Yao TC, Chung HT, See LC, Kuo ML, Huang JL. Polymorphisms in the promoter region of RANTES and the regulatory region of monocyte chemoattractant protein-1 among Chinese children with systemic lupus erythematosus. J Rheumatol 2004;31:2062-7.
21. Ye DQ, Yi SH, Xiang PL, et al. The correlation between monocyte chemoattractant protein-1 and the arthritis of sytemic lupus erythematosus among Chinese. Arch Dermatol Res 2005;;296:366-71.
22. Hochberg M. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997;40:1725.
23. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630-40.
24. Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996;39:363-9.
25. Von Feldt J, Eisner E, Sawires A. Coronary electron beam computed tomography in 13 SLE patients with two or more cardiovascular risk factors. J Clin Rheumatol 2002;8:316-21.
26. Levey AS, Bosch J, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-70.